You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
POINT-OF-CARE ELECTROCHEMICAL APTASENSOR FOR LONG-TERM PHARMACOLOGICAL ADHERENCE MONITORING
SBC: GUILD ASSOCIATES INC Topic: 114Point-of-Care HIV Viral Load, Drug Resistance, and Adherence Assays: The long-term goals of this program are to develop novel, low-cost, real-time point-of-care (POC) assays for 1. HIV Viral Load Monitoring; 2. HIV Drug Resistance Monitoring; and 3. Pharmacological Adherence Monitoring. This contract aims to develop an electrochemical aptamer-based sensor device for simple, rapid, and low-cost det ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
SCREENING FOR TOLEROGENIC ADJUVANTS TO ENHANCE ANTIGEN SPECIFIC IMMUNOTHERAPY FOR CELIAC DISEASE.
SBC: Qrono, Inc. Topic: 116Celiac disease (CD) is a human chronic autoimmune disorder of the small intestine driven by adaptive immune responses to gluten peptides in wheat, barley, and rye. The contractor is targeting dendritic cells and macrophages to discovery new tolerogenic adjuvants which when paired with gluten antigens, may enable the first clinically viable immunotherapy for CD patients.
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151.
SBC: MOLECULAR EXPRESS, INC Topic: 116The contractor will generate analogues of signal modifiers and co-formulate them with monophosphoryl lipid A using the contractor’s proprietary VesiVax liposomal system.
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
POP TECHNOLOGIES, INC., ""MULTIVALENT QS-18 PROTEIN NANOPARTICLES FOR A BROADLY PROTECTIVE INFLUENZA VIRUS VACCINE"".
SBC: POP Biotechnologies Inc. Topic: 117The COVID-19 pandemic has underscored the importance of not only vaccines but also vaccine adjuvants. Plant saponins have yielded some of the most powerful vaccine adjuvants to date. This project seeks to combine and develop QS-18, a commercially viable and highly abundant saponin, with spontaneous nanoliposome antigen particlization technology based on cobalt porphyrin-phospholipid (CoPoP), which ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
TEICHOS LABORATORIES, LLC. ""AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT"".
SBC: TEICHOS LABORATORIES, LLC Topic: 117The project will optimize a novel adjuvant formulation composed of alum and TL-001, a unique totally synthetic peptidoglycan (sPGN) TLR2 agonist, to improve performance of a registered DTaP subunit vaccine. Preliminary results with TL-001 strongly suggest potential as a non-toxic, single agent vaccine adjuvant. TL-001 and a phosphonylated analogue (pTL-001) will be prepared and their respective af ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
TENDEL THERAPIES, INC. (75N93023C00030) TITLE: TFH-TARGETING GENETIC ADJUVANTS TO PROMOTE DURABLE ANTI-INFLUENZA STEM ANTIBODIES IN OLDER ADULTS.
SBC: TENDEL THERAPIES INC Topic: 117The project is focused on progressing BiTar-s3, a vaccine adjuvant agent. The project will develop a vaccine that targets HA stem epitopes shared across many flu-A strains, thereby addressing the difficulty of eliciting heterosubtypic neutralizing antibodies (nAb) against influenza. Specifically, the project’s aims are constructing immunogens fused to the BiTar-s3 adjuvant, to select a lead vacc ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
SBIR NEW AWARD TO SKY PARK LABS, LLC
SBC: SKY PARK LABS LLC Topic: 121To develop a user-friendly software interface designed to inform point-of-care diagnostic decision making for infectious diseases.
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
DESIGN AND DEVELOP A NOVEL APPROACH TERMED 3IN1 TO EFFICIENTLY COLLECT SAMPLES IN FIELD LOCATIONS (BLOOD SPUTUM URINE) TO SUPPORT SURVEILLANCE ACTIVITIES TO IDENTIFY NEW VIRUSES OF PANDEMIC POTENTIAL
SBC: LYNNTECH INC. Topic: 120TO DESIGN AND DEVELOP A NOVEL APPROACH TO EFFICIENTLY COLLECT SAMPLES (E.G., BLOOD) IN FIELD LOCATIONS TO SUPPORT SURVEILLANCE ACTIVITIES TO IDENTIFY NEW VIRUSES OF PANDEMIC POTENTIAL.
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
IMPLEMENT EXTRACTION COMPATIBILITY WITH WHOLE BLOOD AND TISSUE LYSATES WITH INDUSTRY ACCEPTABLE BIOSAFETY STANDARDS THAT INCLUDE STERILIZATION AND PRODUCE AN INSTRUMENT DESIGNED WITH PORTABILITY AND R
SBC: Redbud Labs, Inc. Topic: 120To advance the capacity for sample processing and pathogen discovery in the field to improve downstream diagnostic applications.
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Commercial Readiness for Direct-to-Digital Pathology
SBC: APPLIKATE TECHNOLOGIES, INC. Topic: NCIAbstract Project Summary Applikate Technologies has developed Clearing Histology with Multiphoton Microscopy (CHiMP), a novel tissue processing and imaging platform that provides direct-to-digital images from intact pathology tissue specimens, such as biopsies, without the need for wax embedding, slicing, or scanning of slides. The application of this technology to cancer diagnosis will reduce err ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health